Pharmabiz6d
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate
IBI3009 has already obtained IND approvals in Australia, China, and the US, with the first patient for the phase 1 study dosed in December 2024. This collaboration aims to bring innovative treatment ...
조선일보7d
Roche secures cancer-fighting ADC from Innovent in $1 billion deal
Innovent Biologics announced on the 2nd (U.S. local time) that it has signed a global development and sales license (technology transfer) agreement with Roche for the ADC "IBI3009," which is being ...
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...
High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
FiercePharma6d
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Business Insider7d
Innovent Biologics: Strategic Partnerships and Robust Pipeline Drive Buy Rating
The company’s recent strategic partnership with Roche for the global rights of its DLL3 ADC, IBI3009, positions it favorably in the international market. This collaboration not only brings an ...
precisionmedicineonline6d
Innovent's Dovbleron Gains Approval in China for ROS1-Positive NSCLC
Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...